Aptose to Present at RBC Capital Markets 2022 Global Healthcare Conference


Aptose Biosciences, Inc.

SAN DIEGO and TORONTO, May 03, 2022 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing kinase inhibitors to treat hematological malignancies, today announced that Dr. William G. Rice, Chairman, President and CEO of Aptose, will be attending the RBC Capital Markets Global Healthcare conference:

RBC Capital Markets Global Healthcare Conference 2022


May 17, 2022


3:30 p.m. – 4:00 p.m. ET


Fireside Chat hosted by Gregory J. Renza, MD, Equity Research – Biotechnology



The Aptose leadership team will also hold 1×1 meetings during the events.

About Aptose

Aptose Biosciences is a clinical-stage biotechnology company engaged in the development of personalized therapies addressing unmet medical needs in oncology, with an initial focus on hematology. The Company’s pipeline of small molecule cancer therapeutics includes products designed to provide single-agent efficacy and to enhance the efficacy of other cancer therapies and regimens without overlapping toxicities. The Company has two clinical-stage investigational products in development for hematological malignancies: HM43239, an oral myeloid kinome inhibitor in an international phase 1/2 trial in patients with relapsed or refractory acute myeloid leukemia (AML); and luxeptinib, an oral, lymphoid and myeloid kinome inhibitor, in a Phase 1 a/b trial in patients with relapsed or refractory B-cell malignancies who have failed or are intolerant to standard treatments, and in a trial of separate Phase 1 a/b in patients with relapsed or refractory AML or high-risk myelodysplastic syndrome (MDS). For more information, visit www.aptose.com.

For more information, please contact:

Aptose Biosciences Inc.
Susan Pietropaolo
Investor Relations
[email protected]

LifeSci Advisors, LLC
Dan Ferry, General Manager
[email protected]

Source link


Comments are closed.